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Programmed Death 1 (PD-1) expression by human/simian immunodeficiency virus (HIV/SIV)-specific CD8 T cells has been
associated with defective cytokine production and reduced in vitro proliferation capacity. However, the cellular mechanisms
that sustain PD-1high virus-specific CD8 T cell responses during chronic infection are unknown. Here, we show that the PD-1high
phenotype is associated with accelerated in vivo CD8 T cell turnover in SIV-infected rhesus macaques, especially within the SIV-
specific CD8 T cell pool. Mathematical modeling of 5-bromo-2= deoxyuridine (BrdU) labeling dynamics demonstrated a signifi-
cantly increased generation rate of PD-1high compared to PD-1low CD8 T cells in all memory compartments. Simultaneous analy-
sis of Ki67 and BrdU kinetics revealed a complex in vivo turnover profile whereby only a small fraction of PD-1high cells, but
virtually all PD-1low cells, returned to rest after activation. Similar kinetics operated in both chronic and acute SIV infection. Our
data suggest that the persistence of PD-1high SIV-specific CD8 T cells in chronic infection is maintained in vivo by a mechanism
involving high production coupled with a high disappearance rate.
The expression of ProgrammedDeath 1 (PD-1) has been linkedto CD8 T cell dysfunction, especially defective cytokine pro-
duction and impaired in vitro proliferation capacity, in human/
simian immunodeficiency virus (HIV/SIV) infection (1–5).
Chronic T cell receptor (TCR)-mediated stimulation is necessary
to maintain high PD-1 expression on SIV-specific CD8 T cells (6)
and, most likely, on HIV-specific CD8 T cells (7). Furthermore,
PD-1 expression correlates with reduced antigen-specific CD8 T
cell survival in vitro (8–10). However, it is not known whether
PD-1 CD8 T cell survival is compromised in vivo.
Several studies have described in vivo T cell dynamics during
HIV and SIV infection (11–17). It is clear from this body of work
that bothHIV and SIV infection lead to increased turnover ofCD4
and CD8 T cells in vivo. Although the interpretation of labeling
studies that focused on CD4 T cell kinetics was confounded by the
fact that these cells are the major targets for cytopathic viral infec-
tion, it became clear that increased turnover of CD4 and CD8 T
cells alike is primarily a physiological consequence of incessant
immune activation, both specific and nonspecific (18). The study
of CD8 T cell dynamics is therefore important, not only in its own
right, but also as a paradigm for understanding the consequences
of ongoing immune activation.
It is unclear how a large population of PD-1 antigen-specific
CD8 T cells is maintained in the presence of continuous HIV/SIV
replication, especially when all data suggest a critical role for
chronic antigen stimulation, which should also induce apoptosis.
One possibility is that PD-1 virus-specific CD8 T cells are main-
tained via slow production and slow clearance, suggesting that
they do not actually undergo apoptosis in response to in vivo stim-
ulation as they do in vitro, perhaps due to an altered cytokine
environment. Alternatively, these cells could persist in a more
dynamic state of high production and high clearance, constantly
replenished from a population of PD-1 virus-specific CD8 T
cells. To distinguish between these two possibilities, we investi-
gated the turnover of bulk and SIV-specific CD8 T cell popula-
tions by analyzing the cellular incorporation of 5-bromo-2=de-
oxyuridine (BrdU) in SIV-infected rhesus macaques.
MATERIALS AND METHODS
Animals. Four colony-bred rhesus macaques (Covance Research Prod-
ucts), housed and handled in accordance with the standards of the Amer-
ican Association for the Accreditation of Laboratory Animal Care, were
infected intravenously (i.v.) with SIVmac251. All animal studies were ap-
proved by the Animal Care and Use Committees of the Vaccine Research
Center, National Institute of Allergy and Infectious Diseases, NIH. Viral
loads were measured using a QIAamp Viral RNA Mini Kit (Qiagen) at
Duke Human Vaccine Institute, Durham, NC. Peripheral blood mono-
nuclear cells (PBMCs) were isolated from whole blood by centrifugation
over an isotonic discontinuous Percoll (Sigma) density gradient (35% to
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60% [vol/vol]). After washing, the cells were cryopreserved until further
use.
Antibodies. Directly conjugated monoclonal antibodies (MAbs) and
other fluorescent reagents were obtained from the following vendors:
(i) CD3-Cy7APC (allophycocyanin), CD95-Cy5PE (phycoerythrin),
BrdU-APC, andKi67-FITC (fluorescein isothiocyanate) fromBDBio-
sciences; (ii) CD8-QD655, streptavidin-Cy7PE, fixable violet amine vi-
ability dye (ViViD), and quantum dots from Life Technologies; and (iii)
CD28-ECD (energy-coupled dye) from Beckman Coulter. Polyclonal
PD-1–biotin was obtained from R&D Systems. The fluorescent-pep-
tide–Mamu-A*01 tetrameric complexes central memory 9 (CM9)-PE
(Gag, CTPYDINQM; residues 181 to 189) and TL8-PE (Tat, TTPESANL;
residues 28 to 35) were produced in house, as described previously (19).
Flow cytometry. Briefly, 2  106 to 3  106 cells were washed and
stained sequentially with ViViD, PD-1–biotin, and fluorochrome-la-
beled streptavidin. After two further washes, the cells were incubated with
tetramer at 37°C for 20 min, washed twice, and surface stained with
CD8, CD28, and CD95 for 20 min, and then fixed with 1 fluores-
cence-activated cell sorter (FACS) lysing solution (BD Biosciences) and
permeabilized with a Cytofix/Cytoperm Kit (BD Biosciences). The cells
were then treated with DNase (APC BrdU Flow Kit; BD Biosciences) for
30 min at 37°C, washed with Perm/Wash buffer (Cytofix/Cytoperm Kit;
BD Biosciences), and stained intracellularly with CD3, BrdU, and
Ki67. The gating scheme is shown in Fig. S1A in the supplemental
material. The CD28dim CD95low (here referred to as naive) CD8 T cell
population was used to define PD-1high and PD-1low expression. Cells
were analyzed using a modified LSRII flow cytometer (BD Immuno-
cytometry Systems). Between 500,000 and 106 events were acquired for
each condition. Antibody capture beads (BD Biosciences) stained sep-
arately with the individual MAbs used in the test samples were used for
electronic compensation. Data analysis was performed using FlowJo
version 9.0.1 (TreeStar). The forward scatter area (FSC-A) versus for-
ward scatter height (FSC-H) profile was used to gate out cell aggre-
gates; ViViD was used to exclude apoptotic cells. After selection based
on CD3 positivity, BrdU and Ki67 expression was measured in gated
CD4, CD8, and tetramer CD8 T cells with respect to differentiation
status and PD-1 expression.
In vivo administration of BrdU. BrdU (Sigma) was dissolved in
Hanks balanced salt solution (Life Technologies) at 10mg/ml, pH7.4, and
sterile filtered into autoclaved bottles. Macaques received 30 mg/kg body
weight of BrdU daily via i.v. injection on four consecutive days. Bloodwas
collected on days 1 (pre-BrdU injection, basal level), 2, 3, 4, 7, 9, and 14 for
acute-phase studies; blood samples were collected on days 22 and 31, in
addition, for chronic-phase studies. The same macaques were studied in
both acute- and chronic-phase SIV infection using separate courses of
BrdU administration.
Mathematicalmodel.A system of coupled ordinary differential equa-
tions (ODE) was defined to explore the kinetic behavior of three different
cell states defined as resting (R), activated (A), and effector (E). In this
model, resting cells can become activated at rate a, and activated cells can
divide at rate p or differentiate (at rate e) into effectors that can disappear
at rate d or return to rest (state R) at rate r. The differential equations
for the time evolution of the population sizes are as follows: (d/dt)R r
E a R, (d/dt)A a R (p e) A, and (d/dt)E e A (d
r) E.
The BrdU labeling and delabeling process was simulated by assuming
that during the labeling phase, cells that divided became BrdUhigh,
whereas during the delabeling phase, cells that divided lost BrdU on aver-
age in four steps, meaning that four divisions were necessary to transition
from BrdUhigh to an unlabeled state. This “minimal model” simplifies the
dilution process because the BrdU population generated during the label-
ing period is heterogeneous in terms of labeling intensity; thus, some
labeled cells that continue to divide become negative earlier than others.
Mathematically, this was captured by using five subgroups of R, A, and E,
corresponding to four BrdU groups and one BrdU group. The param-
eters r, a, e, p, and d of themodel were fitted against the experimental data
(fractions of BrdU cells, total and Ki67, in blood over time) using the
above ODEs in MATLAB (details can be found in the supplemental ma-
terial). Steady state was assumed and confirmed experimentally (see Fig.
S1B in the supplemental material).
Statistical analysis. All statistical analyses were performed using
GraphPad Prism (GraphPad Software). P values were calculated using the
Mann-Whitney U test, and values of 0.05 were considered significant.
The mean values standard errors are also presented. BrdU decay rates
were calculated assuming first-order kinetics. The natural log of the per-
centage of BrdUhigh CD8 T cells was plotted against time. These data were
fitted to a straight line using themethod of least squares and the first-order
rate constant determined from the slope of the line.
RESULTS
High turnover ofCM9PD-1highCD8Tcells during the chronic
phase of SIV infection. To investigate the in vivo dynamics of
rigorously defined T cell populations in rhesus macaques 3 to 4
months after SIVmac251 infection, we conducted a serial analysis
of BrdU incorporation using flow cytometry and mathematical
modeling (Fig. 1a). No BrdU integration was detected in naive
CD8 T cells, indicating very slow in vivo turnover within the com-
partment (Fig. 1b). In agreement with previously published data
(6), almost all CM9-specific CD8 T cells were found to express a
PD-1high phenotype (see Fig. S1A and B in the supplemental ma-
terial). BrdU incorporation was higher in the CD28high CD95high
population ofCM9PD-1high CD8T cells than in the correspond-
ing CD28low CD95high population (57.7  2.9 versus 22.5  2.1,
maximumpercentage of BrdUhigh cells; P 0.0294) (Fig. 1b). The
accumulation of BrdU was also accelerated in the CM9 PD-1high
CD28high CD95high population (peak on day 3 or 4) compared to
the CM9 PD-1high CD28low CD95high population (peak on day 5
or 6) (Fig. 1b; see Fig. S2 in the supplemental material). Addition-
ally, CM9CD8 T cells incorporated significantly larger amounts
of BrdU than matched bulk CD8 T cells in both the CD28high
CD95high (26.2 2.4,maximumpercentage of BrdUhigh cells) and
CD28low CD95high (15.4 1.5, maximum percentage of BrdUhigh
cells) populations. Both CM9 and bulk CD8 T cell populations,
however, exhibited similar kinetics of BrdU incorporation (Fig.
1b). The frequency of TL8 SIV-specific CD8 T cells during the
chronic phase was very low (see Fig. S1B in the supplemental
material), making the analysis of BrdU incorporation problem-
atic. Analysis of bulk memory CD8 T cell subsets revealed higher
in vivo incorporation of BrdU in the PD-1high CD28high CD95high
population than in the PD-1high CD28low CD95high population
(26.2  2.4 versus 15.4  1.5, maximum percentage of BrdUhigh
cells; P  0.0286) (Fig. 1b). Similarly to CM9 CD8 T cells, the
kinetics of BrdU incorporation differed between these two popu-
lations; BrdU accumulation peaked at day 3 or 4 for the PD-1high
CD28high CD95high population, while the peak for PD-1high
CD28low CD95high cells occurred on day 5 or 6. PD-1low cells were
characterized by lower in vivo incorporation of BrdU than
PD-1high cells in both memory compartments (Fig. 1b; see Fig. S2
in the supplemental material).
BrdUdecay rates were calculated assuming first-order kinetics.
As expected, no decay was apparent in the naive population (Fig.
1c, left). The decay rate was significantly higher in CM9 cells
(0.418  0.028 per day) than in the bulk CD28high CD95high
(0.234  0.044 per day; P  0.013) and CD28low CD95high
(0.177 0.016 per day; P 0.0003) CD8 T cell populations (Fig.
1c, left).We further analyzedBrdUdecay rates in individualmem-
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ory populations with respect to PD-1 levels (Fig. 1c, right). Again,
significantly higher decay rates were found for CM9 cells than
for bulk PD-1high CD8 T cells in both memory populations
(0.651  0.09 versus 0.338  0.032 per day, CD28high CD95high,
P  0.021; 0.453  0.02 versus 0.231  0.015 per day, CD28low
CD95high, P 0.0004). Furthermore, a trend toward higher decay
rates in CM9 CD28high CD95high cells than in CM9 CD28low
CD95high cells was observed (Fig. 1c, right). Interestingly, bulk
PD-1high CD8 T cells were characterized by significantly higher
BrdU decay rates than for PD-1low CD8 T cells in both memory
compartments (0.338  0.032 versus 0.147  0.014 per day,
CD28high CD95high, P  0.0026; 0.231  0.015 versus 0.121 
0.018 per day, CD28low CD95high, P  0.004) (Fig. 1c, right).
Overall, our data point to accelerated in vivo turnover of CM9
PD-1high CD8 T cells and indicate that PD-1low CD8 T cells have
the lowest turnover among the populations tested.
CM9 PD-1high CD8 T cells are characterized by high in vivo
generation rates.Despite the high in vivo turnover of CM9CD8
T cells, the percentage (0.7%) of these cells in the periphery
remained relatively constant over the 31 days of observation (see
Fig. S1B in the supplemental material). Analysis of PD-1 and Ki67
expression revealed a similar steady state for all populations tested
(see Fig. S1B in the supplemental material). These are important
prerequisites for themodeling approach used here, which is there-
fore not well suited to acute-phase analyses. To explore the pro-
liferation and disappearance kinetics of the various populations
more thoroughly, we analyzed in vivo turnover using a simple
five-parameter ODE model (Fig. 2a). Due to the limited number
of data points, we opted for a simple model that nevertheless ac-
counts for the fact that activated cells will first proliferate and then
contract (differentiate, die, and disappear). A simpler model with
only four parameters, according to which cells were assumed to
proliferate and disappear simultaneously, was able to fit the ob-
served total BrdU uptake and BrdU loss kinetics for most cell
populations but failed to reproduce the kinetics of the appearance
of Ki67 BrdU cells (Fig. 2a, bottom); this observation empha-
sizes the importance of taking into account the time-structured
“cohort” behavior of activated cells (18, 20). A representative “fit-
ting curve,” generated by fitting the parameters of this model to
one of our data sets, is shown in Fig. 2a (bottom). The complete set
of fits is provided in Fig. S2 in the supplemental material. CM9
CD8 T cells were characterized by higher activation/proliferation
rates than bulk CD8 T cells in both the CD28high CD95high and
CD28low CD95high compartments (Fig. 2b). The generation rate
was calculated based on the product of the proliferation rate and
the fraction of activated cells in each particular population. CM9
CD8 T cells had a significantly increased generation rate com-
pared to PD-1high bulk memory (CD28high CD95high and CD28low
CD95high) CD8 T cells (Fig. 2b). Cells with low PD-1 expression
had the lowest generation rates in both memory populations. A
striking hierarchy was also apparent with respect to the fraction of
resting cells. In particular, CM9 CD28high CD95high CD8 T cells
displayed the smallest fraction of cells in the resting state (40%),
while substantially larger fractions were observed in the bulk
memory populations, especially those with low levels of PD-1 ex-
pression. Taken together, our data indicate that a high-genera-
tion/high-disappearance mechanism underlies the maintenance
of antigen-specific and bulk PD-1high CD8 T cell populations in
chronic SIV infection.
Only a small fractionof activatedPD-1highCD8Tcells return
to a resting state. Next, we analyzed the in vivo kinetics of indi-
vidual CD8T cell populations according to the expression of Ki67,
an activation/proliferation marker that is downregulated when
cells return to a resting state. Themajority of CM9 cells displayed
a Ki67high phenotype in both the CD28high CD95high (79.69 
1.78) and CD28low CD95high (52.78 1.28) populations (see Fig.
S1B in the supplementalmaterial). Among BrdU cells, coexpres-
sion of Ki67 can be divided into three populations (Ki67high
BrdUhigh, Ki67dim BrdUhigh, and Ki67low BrdUhigh) and tracked
over time (Fig. 3a). Analyzing the in vivo BrdU label contents in
these populations for both CM9 and total CD8T cells allowed us
FIG 1 PD-1high SIV-specific CD8 T cells are characterized by high in vivo
turnover. (a) Schematic representation of BrdU administration and blood
collection during the chronic phase of SIV infection. D, day; w, week. (b) BrdU
kinetics in CM9 and bulk memory CD8 T cells. The error bars indicate
standard errors. (c) Dot plots depicting BrdU decay rates in naive, bulk mem-
ory, and CM9 CD8 T cell populations (left) with stratification for PD-1
expression (right). Decay rates were calculated assuming first-order kinetics.
The horizontal bars indicate mean values. P values were calculated using the
Mann-Whitney U test.
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to follow the kinetics of activation and return to rest. In the CM9
CD28high CD95high population, BrdU peaked at day 3 or 4 in the
Ki67high BrdUhigh state, followed by the Ki67dim BrdUhigh (peak at
day 6 or 7) and Ki67low BrdUhigh (peak at days 13 to 20) popula-
tions (Fig. 3b, top). It is noteworthy, however, that these state
transitions do not take place in the peripheral blood, where cells
appear only very transiently; rather, the blood samples provide a
window into the kinetics that take place in the lymph nodes. Im-
portantly, more cells expressed the Ki67high BrdUhigh phenotype
thanprogressed to the subsequent populationswith lower levels of
Ki67 expression (Fig. 3b, top). This phenomenonwasmore prom-
inent in the CM9 CD28high CD95high population than in the
CM9 CD28low CD95high population (Fig. 3b, bottom), thereby
confirming our computational analysis, which had indicated a
clear hierarchy in the ability of cells to return to rest after activa-
tion (Fig. 2b). Analysis of bulk CD8 T cells revealed a similar loss
(through death or migration into the tissues) of cells during tran-
sition from an activated to a resting state in the PD-1high compart-
ment, especially in the CD28high CD95high population (Fig. 3b).
Interestingly, this was not the case for bulk CD8 T cells expressing
a PD-1low phenotype, where BrdUhigh cells transitioned through
the phases of Ki67 expression without substantial loss in total cell
numbers (Fig. 3b). Next, the BrdU decay rates were calculated
for CD8 T cell populations in the Ki67high BrdUhigh and Ki67dim
BrdUhigh compartment. Again, the CM9 CD8 T cell population
showed the highest decay rate among all populations tested,
reaching statistical significance in the Ki67high BrdUhigh CD28low
CD95high (0.811  0.011 versus 1.044  0.09 per day, bulk PD-
1high versus CM9 CD8 T cells; P 0.043) and Ki67dim BrdUhigh
CD28high CD95high (1.001  0.04 versus 1.417  0.09 per day,
bulk PD-1high versus CM9CD8 T cells; P 0.007) cellular com-
partments (Fig. 3c). Bulk PD-1high CD8 T cells were consistently
characterized by higher BrdU decay rates than bulk PD-1low CD8
T cells in all populations tested (Fig. 3c), reflecting rapid prolifer-
ation-induced label dilution and replacement of labeled cells by
unlabeled cells in the PD-1high compartment.
High turnover of CM9 PD-1high CD8 T cells during the
acute phase of SIV infection. In further experiments, we investi-
gated the in vivo dynamics of BrdU incorporation 4 weeks after
SIVmac251 infection (Fig. 4a). A low, transient integration of
BrdU was observed in the CD28dim CD95low CD8 T cell popula-
tion (Fig. 4b). Similar to the chronic phase of SIV infection, BrdU
incorporation was highest in the CM9 compartments of both
memory CD8 T cell subsets (Fig. 4b; see Fig. S3 in the supplemen-
talmaterial); furthermore, BrdU loss was accelerated in the CM9
population compared to matched bulk memory CD8 T cells (Fig.
4b). In contrast to the situation in chronic SIV infection, however,
bulk PD-1high CD28high CD95high and PD-1high CD28low CD95high
CD8 T cells showed similar maximum levels of BrdU incorpora-
tion (33  6.6 versus 32.7  7.6, maximum percentage of
BrdUhigh cells) (Fig. 4b). BrdU decay rates were significantly
higher in CM9 CD8 T cells (0.496  0.05) than in bulk CD8 T
cells in both the CD28high CD95high (0.183  0.03 per day; P 
0.004) and CD28low CD95high (0.195  0.01 per day; P  0.002)
compartments. Additionally, the PD-1low population displayed
lower decay rates than the PD-1high population in both the
FIG2 PD-1high SIV-specificCD8T cells are characterized by high in vivo generation rates. (a) Graphic overview of themodel used to analyze specific populations
(top) and representative fitting curves for BrdU levels in the indicated cell populations from one macaque (bottom). The red data points and curve correspond
to the total BrdU uptake; the blue data points and curve represent only the Ki67 BrdU cells. (b) Calculated fractions of resting cells, proliferation rates, and
generation rates, calculated as the product of the fraction of activated cells and the proliferation rate, in the various phenotypically distinct populations. The bars
depict mean values plus standard errors.
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FIG3 Themajority of PD-1high CD8T cells do not return to a resting state. (a) Flow cytometry plots depicting the subpopulations of PD-1high CD28high CD95high
CD8 T cells identified by simultaneous analysis of Ki67 and in vivo integrated BrdU at several time points after BrdU administration. Numbers represent the
relative frequency of the population in the box. (b) BrdU kinetics in total CM9 and bulk memory CD8 T cell populations with stratification for Ki67 and BrdU
levels. (Top)CD28high CD95high populations. (Bottom)CD28lowCD95high populations. (c) BrdUdecay rates inmemory subsets of PD-1low, PD-1high, andCM9
CD8 T cells with stratification for Ki67 expression. (Left) Ki67high BrdUhigh CD8 T cells. (Right) Ki67dim BrdUhigh CD8 T cells. The horizontal bars depict mean
values, and the error bars indicate standard errors. P values were calculated using the Mann-Whitney U test.
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CD28high CD95high (0.143 0.03 versus 0.368 0.04 per day; P
0.004) andCD28lowCD95high (0.094 0.017 versus 0.185 0.039
per day; P 0.07) subsets. As in the chronic phase, simultaneous
analysis of BrdU and Ki67 expression revealed complex BrdU dy-
namics in both the CM9 and bulk CD8 T cell populations (Fig.
4c). A large difference in maximum BrdU incorporation was ap-
parent between Ki67high and Ki67dim CM9 cells (Fig. 4c), indic-
ative of the fact that only a small fraction of such cells return to rest
after activation. This profile was apparent for both the CD28high
CD95high (56.78 3.19 versus 7.41 1.3, Ki67high BrdUhigh versus
Ki67dim BrdUhigh; P  0.0001) and CD28low CD95high (34.35 
7.74 versus 16.43  2.19, Ki67high BrdUhigh versus Ki67dim
BrdUhigh; P  0.06) populations (Fig. 4c and data not shown).
Again, CM9 CD8 T cells showed the highest decay rates of all
populations tested, even during acute infection (Fig. 4d). There-
fore, the in vivo dynamic profile of CD8 T cell populations during
FIG 4 High in vivo turnover of CM9 PD-1high CD8 T cells during acute SIV infection. (a) Schematic representation of BrdU administration and blood
collection during the acute phase. (b) BrdU kinetics in CM9 and bulk memory CD8 T cells during the acute phase with stratification for PD-1 expression. (c)
BrdUkinetics inCM9 (left) and bulkmemory (middle and right) CD8T cells during the acute phasewith stratification forKi67 andBrdU levels. (d) BrdUdecay
rates inmemory subsets of PD-1low, PD-1high, andCM9CD8T cells during the acute phase with stratification for Ki67 expression. (Left) Ki67high BrdUhigh CD8
T cells. (Right) Ki67dim BrdUhigh CD8 T cells. The horizontal bars depict mean values, and the error bars indicate standard errors. P values were calculated using
the Mann-Whitney U test.
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the acute phase is similar to that observed in the chronic phase of
SIV infection.
DISCUSSION
Recently published work has shown that PD-1 could serve as a
regulator of antigen-specific CD8 T cell survival (9, 21, 22). In
particular, the level of PD-1 expression correlates with in vitro
sensitivity to cell death in both HIV (9) and SIV (6) infection.
This in vitro phenotype raises the question of what cellular
mechanism(s) supports the sustained PD-1high HIV/SIV-spe-
cific CD8 T cell populations observed in vivo. We considered
two possibilities. First, the rapid disappearance of PD-1high vi-
rus-specific CD8 T cells may be counterbalanced by rapid pro-
duction (high generation/high disappearance). Second, PD-
1high CD8 T cells may not be as susceptible to apoptosis in vivo
as they are in vitro, in which case a low generation/low disap-
pearance rate could sustain PD-1high virus-specific CD8 T
cells. The current study was designed to investigate the relative
impacts of these mechanisms in mediating the potential pro-
apoptotic function of PD-1. Accordingly, the in vivo turnover
rates of several rigorously defined CD8 T cell populations with
respect to PD-1 expression were determined in SIV-infected
rhesus macaques.
Several previous studies have shown a significantly increased in
vivo turnover of CD8 T cells in SIV-infected monkeys compared
to noninfected animals (12, 14, 17). Furthermore,memory CD8T
cells were found to express a phenotype characterized by acceler-
ated in vivo accumulation of BrdU, followed by rapid loss com-
pared to naive CD8 T cells (12, 17), indicative of increased prolif-
eration/disappearance of the former cells. In our study, no BrdU
integrationwas found in the “naive” CD28dim CD95low CD8T cell
compartment during the chronic phase, and only transient BrdU
integration in a small fraction of these cells was observed during
the acute phase. Furthermore, only very low levels (1%) of BrdU
incorporation were detected before SIV infection, even in the PD-
1high bulkmemoryCD8T cell compartment. This finding is in line
with the very low levels of Ki67 expression previously reported in
this population of cells in non-SIV-infected animals (23) and in-
dicates that PD-1 does not demarcate proliferation by itself. Fur-
thermore, the short timewindow (4 days) of BrdU administration
in this study likely only permits the detection of cell populations
with high turnover rates, in contrast to previous studies in which
BrdU was given for 2 to 4 weeks (12, 14, 17). As expected, SIV-
specific CD8 T cells were characterized by higher turnover rates
than bulk CD8 T cells in both memory compartments tested. Ad-
ditionally, high expression of PD-1 was consistently associated
with higher in vivo turnover in all populations tested. This was
more prominent in the less differentiatedCD28high CD95high pop-
ulation than in the CD28low CD95high population for both total
and SIV-specific CD8 T cells. The kinetics of BrdU integration
were also found to be different in these two memory subsets, but
only in the PD-1high compartment. Thus, PD-1high CD28high
CD95high cells accumulated BrdU faster and reached maximum
integration earlier than PD-1high CD28low CD95high cells. Al-
though the peak of BrdU integrationwas different, similar kinetics
applied to SIV-specific and bulk CD8 T cells in the same memory
compartment. These findings indicate that the expression of coin-
hibitory receptors, such as PD-1, as well as differentiation status,
plays an important role in the regulation of CD8 T cell prolifera-
tion/disappearance in vivo.
The relative representation of phenotypically distinct CD8 T
cell populations was found to be quite constant during the period
of investigation in both the chronic and acute phases of SIV infec-
tion. An important aspect of this profile relates to whether a cell
that starts out in one phenotype can be assumed to end in another
phenotype. To explore this issue further, we would require far
more data, because themodels would include parameters for phe-
notypic transitions (differentiation steps). As our model does not
allow for such transitions, we assumed the presence of a popula-
tion that can receive a certain degree of stimulation and appear as
PD-1 in the blood. The data and the model show that most of
these cells received a potent stimulus and rapidly underwent sev-
eral divisions, after which they quickly disappeared. In agreement
with our previous data (6), the vastmajority of SIV-specificCD8T
cells expressed a PD-1high phenotype during the chronic phase.
This profile was associated with significantly higher Ki67 expres-
sion than in bulk PD-1high CD8 T cells in both memory compart-
ments tested, while PD-1low cells expressed the lowest levels of
Ki67. The application of a mathematical model revealed signifi-
cantly higher generation rates in the SIV-specific CD8 T cell com-
partment than in bulk PD-1high populations; PD-1low cells dis-
played the lowest generation rates. Expression of Ki67, amarker of
CD8 T cell activation, therefore, correlates with the in vivo turn-
over of total and virus-specific CD8 T cells during chronic SIV
infection. This finding agrees with previously reported data from
studies of HIV infection (15).
In the case of SIV-specific CD8 T cells, the loss of BrdU was
found to follow a biphasic mode, with a rapid decline (before day
9) followed by a slower phase (after day 9). Such a biphasic mode
was previously reported in other studies of HIV (13) and SIV (24)
infection. The loss of BrdU could be due to cell death,migration to
different anatomical compartments, and/or dilution in cells that
continue to divide. Loss of Ki67 expression by BrdU-labeled cells
after discontinuation of BrdU administration identifies cells that
have stopped dividing, while the persistence of a population of
cells with high levels of Ki67 expression but diminishing BrdU
intensity helps to identify cells that continue to divide (16, 24).We
therefore investigated the in vivo turnover of CD8 T cell popula-
tions further by analyzing the kinetics of cells coexpressing BrdU
and Ki67. BrdU dynamics were found to be dramatically different
between SIV-specific CD8 T cell populations with respect to Ki67
expression. A hierarchy was observed both for peak height and the
rate of decline of BrdU in the different populations tested. The
Ki67high BrdUhigh population exhibited the highest integration/
decline rate of BrdU, followed by the Ki67dim BrdUhigh and
Ki67low BrdUhigh populations. This profilewasmore prominent in
the less differentiated CD28high CD95high memory cell subset. A
similar profile was observed in the bulk PD-1high compartment.
In the PD-1low compartment, all three populations (Ki67high
BrdUhigh, Ki67dim BrdUhigh, and Ki67low BrdUhigh) exhibited sim-
ilar peak heights. Label loss was faster in the PD-1high than in the
PD-1low compartment regardless of Ki67 expression, supporting a
potential proapoptotic role for PD-1 in cells expressing a PD-1high
phenotype. Furthermore, the slower decline of PD-1high BrdU-
labeled cells in the Ki67dim and Ki67low populations than in the
Ki67high population likely stems from a greater disappearance of
BrdUhigh cells in the PD-1high than in the PD-1low compartment.
This conclusion is further supported by the results of our compu-
tational analysis, which indicates a considerably lower rate of re-
turn to rest for PD-1high cells.
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PD-1 is a marker of potent stimulation and demarcates cells that
have received proproliferative signals. In the experimental data, we
cannot distinguish cells that received these stimuli over a prolonged
period of time, performed several divisions, and then assumed a state
that corresponds to desensitization from cells that simply upregu-
lated PD-1 due to recent stimulation, thereby retaining the ability to
undergo rapid division pending receipt of strong inhibitory signals
via PD-1. For themodeling process, however, this lack of distinction
was not critical, because we only assumed the existence of a popula-
tionof cells that canreceiveacertaindegreeof stimulationandappear
as PD-1high in the blood. Again, our data show that the vast majority
of PD-1high cells received strong stimulation, rapidly underwent sev-
eral divisions, and then disappeared.
Our simple computational analysis assumed a self-containedPD-
1high population whose homeostasis is maintained by a (small) frac-
tion of cells returning to rest after activation and proliferation. Rec-
onciling our findings of vigorous proliferation with a previously
assumed role of PD-1 as a marker of defective responsiveness to an-
tigenic stimulation, one could hypothesize that PD-1high T cells, after
leaving a proliferative state, donot return to a pool of cells that can be
restimulated to undergo further rounds of division. Thus, the virus-
specificKi67BrdUPD-1high cells observed in our studymight not
be contributing to the long-term persistence of the PD-1high pheno-
type. One possibility is that new PD-1high virus-specific CD8 T cells
are continuously generated, especially in the setting of chronic infec-
tion.Alternatively, PD-1low cells could continuously convert to aPD-
1high phenotype by upregulating PD-1 upon stimulation/activation.
A more finely resolved kinetic analysis of BrdU incorporation and
phenotypic transition will be necessary to distinguish between these
possibilities.
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